Danielle Brightman
Clinical Director
MPharm PgDip PCert
WEIGHT LOSS TREATMENTS
REDEFINING HEALTH
Obesity has long been attributed to unhealthy lifestyle habits, with traditional outlooks focusing solely on eating less and moving more.
Obesity is complicated, driven by several different factors.
This makes losing weight significantly harder for some people compared to others.
New research on the causes of obesity has prompted the medical community to reevaluate its treatment strategies.
By combining evidence-based weight loss treatments with regular check-ins and accountability, we're setting ourselves up for a longer, healthier life.
| MEDICATION: | MOUNJARO | WEGOVY | ALLI |
|---|---|---|---|
| ACTIVE INGREDIENT: | Tirzepatide | Semaglutide | Orlistat |
| MECHANISM OF ACTION: | Promotes a feeling of fullness and reduces cravings by targeting GLP-1 and GIP receptors | Promotes a feeling of fullness and reduces cravings by targeting GLP-1 receptors | Decreases fat absorption from food |
| EFFECTIVENESS: | Up to 20% weight loss over 17 months with lifestyle changes¹ | Up to 15% weight loss over a year with lifestyle changes² | Around 5% weight loss over a year with lifestyle changes³ |
| DOSAGE: | Self-injected, weekly | Self-injected, weekly | Oral capsule, up to three times daily with meals |
| DOSE ADJUSTMENT: | The standard maintenance dose is 5mg. If a higher dose is needed, you can request an increase, which will be reviewed and approved by your clinician. If approved, your dose will increase gradually in 2.5mg steps - for example, from 5mg to 7.5mg, then to 10mg. If you're already on a higher dose when you join, you'll automatically move to the closest maintenance dose unless you request a different plan. | Increases every four weeks until maintenance dose | Fixed dose, one capsule up to three times daily |
| PRESCRIPTION REQUIRED: | Yes | Yes | No |
*Based on clinical suitability.
Mounjaro (tirzapetide)
Subcutaneous injection
Wegovy (semaglutide)
Subcutaneous injection
Alli (orlistat)
Oral capsule
Obesity: a clinical condition that requires clinical treatment
Obesity is a complex disease influenced by genetics, hormones, and environmental factors.10 Viewing it solely as a matter of lifestyle oversimplifies the challenges many face. Recognising obesity as a disease opens the door to more compassionate, effective treatments.
Numan’s Weight Loss Programme integrates this understanding, helping patients navigate their health journeys with evidence-based medication and expert guidance.
/ "A new way to conquer weight loss")
The role of nutrition, exercise, stress, and sleep
While medications like Wegovy and Mounjaro play a pivotal role in weight management, addressing lifestyle factors is equally crucial for sustained success. Nutrition, exercise, stress, and sleep all influence your ability to lose and maintain weight.
Numan’s expert-led programme incorporates guidance on:
Balanced nutrition to complement your medication
Exercises tailored to your fitness level
Stress management techniques to prevent emotional eating
Sleep optimisation to support metabolism and recovery
These combined elements create a robust framework for long-term health.
The Numan Weight Loss Programme: more than just medication
Numan’s Weight Loss Programme offers a comprehensive, multi-faceted approach to weight management. Medications are supported by expert advice and continuous care, ensuring you receive holistic support.
With the programme, you gain access to:
Clinically-proven weight loss medications
Guidance from a multidisciplinary team of experts
Insights into the complexities of obesity as a disease
By addressing weight loss through multiple angles, the programme empowers you to make lasting changes.
UK DOCTORS AND CLINICIANS
Your expert team
Zoe Griffiths
VP of Behavioural Medicine
BSc (Hons) RD SCOPE
Shivani Sharma-Savani
Obesity Clinical Lead
MPharm PGCert PCert IP
Faye Townsend
Coaching Operational Lead
AfN BSc BDA SENr (Registered Nutritionist)
Jess Uffindell
Registered Nutritionist
BANT CNHC BSc (Hons)
Victoria Rogers
Head of AI Coaching and Behavioural Science
MSc BSc
Dr Aisha Jinnah
Numan Doctor
BSc MBBS MRCGP
Dr Grace Hatton
Women's Health Medical Lead
MBChB MPharm DTM&H MBA
Dr Michael Lacey
Numan Doctor
MBChB BSc (Hons) MRCGP
Dr Alexandra Davidson
Numan Doctor
BSc (Hons) MBBS MRCGP AFHEA MA (Hons) AFMCP
Dr Dimitris Schizas
Numan Doctor
MBBS MRCGP MSC BSSM
References
1. Mounjaro KwikPen 10mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc). (n.d.). Retrieved 24 July 2024, from Org.uk website: https://www.medicines.org.uk/emc/product/15484/smpc
2. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., … the STEP 5 Study Group. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. doi:10.1038/s41591-022-02026-4
3. Mehta, A., Marso, S. P., & Neeland, I. J. (2017). Liraglutide for weight management: a critical review of the evidence. Obesity Science & Practice, 3(1), 3–14. doi:10.1002/osp4.84
4. oplak, H., Ziegler, O., Keller, U., Hamann, A., Godin, C., Wittert, G., … Van Gaal, L. (2005). X‐PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced‐energy diet. Early response to treatment predicts weight maintenance. Diabetes, Obesity & Metabolism, 7(6), 699–708. doi:10.1111/j.1463-1326.2005.00483.x
5. le Roux, C. W., Fils-Aimé, N., Camacho, F., Gould, E., & Barakat, M. (2022). The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy. EClinicalMedicine, 49(101436), 101436. doi:10.1016/j.eclinm.2022.101436
6. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/nejmoa2307563
7. Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc). (n.d.). Retrieved 24 July 2024, from Org.uk website: https://www.medicines.org.uk/emc/product/13799/smpc
This figure is amongst those who used the medication as intended regularly and followed the titration schedule.
8. Saxenda 6 mg/mL solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc). (n.d.). Retrieved 24 July 2024, from Org.uk website: https://www.medicines.org.uk/emc/product/2313/smpc
9. Xenical 120 mg hard capsules - Summary of Product Characteristics (SmPC) - (emc). (n.d.). Retrieved 24 July 2024, from Org.uk website: https://www.medicines.org.uk/emc/product/2592/smpc
10. Lee A, Cardel M, Donahoo WT. Social and Environmental Factors Influencing Obesity. [Updated 2019 Oct 12]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278977/
Start your treatment journey
Answer a few simple questions to get the treatment you need.